A Phase 3 interventional study of Heliox and Air in RSV Infection and Acute Bronchiolitis, sponsored by Wael Seliem. Completed. Open to participants aged 1 Month to 2 Years. Per ClinicalTrials.gov, last updated 2017-05-31.
Sponsored by Wael Seliem · Phase 3, Interventional, and Treatment
Helium is an inert gas with a density almost one-seventh of that of air. Based on its properties breathing a mixture of helium and oxygen (heliox) will lead to a reduction in resistance through narrowed airways and consequently decreases the work of breathing. Participating infants with RSV acute bronchiolitis will be supplied with heliox (ration of 21 oxygen and 79 helium) delivered through a flow nasal cannula to evaluate heliox effect in improving their oxygenation. Heliox will act as an additive therapy to improve oxygenation in patients with lower respiratory tract infection caused by respiratory Syncytial Virus (RSV) and will decrease the need for more complicated therapies.
302 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 48 are open to participants now.
This study's enrollment of 104 is above the median of 89 across 219 interventional studies indexed under Respiratory Syncytial Virus Infections.
Browse Respiratory Syncytial Virus Infections studies →This is the only study on the registry with Wael Seliem as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
receive Helium oxygen mixture 21:79 via nasal cannula 2L/min
Drug: Heliox
receive oxygen 21%via nasal cannula 2L/min
Drug: Air
Heliox (21:79) via nasal cannula 2 litter per minutes
Air 21% via nasal cannula 2 litter per minutes
Improvement in oxygenation
Arterial blood samples will be withdrawn through an arterial stab to determine partial pressure of arterial oxygen (PaO2)
Time frame: change from baseline at 24 hours after treatment
improvement of respiratory distress
measured by the Modified Wood's Clinical Asthma Score
Time frame: change from baseline at 24 hours after treatment
No study locations are listed for this record.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Heliox
Respiratory Syncytial Virus Infections →